What is the latest research on NK cell immunotherapy in Japan?

Latest Research on NK Cell Immunotherapy in Japan

Japan is currently leading a significant portion of the global clinical research into Natural Killer (NK) cell immunotherapy, particularly for solid tumors and hematological malignancies. The latest research shows a clear pivot from using patient-derived, or autologous, NK cells toward allogeneic sources, specifically from cord blood and induced pluripotent stem cells (iPSCs). This shift is driven by data showing that allogeneic NK cells from healthy donors maintain higher cytotoxicity and are less prone to exhaustion in the tumor microenvironment. For instance, a 2024 phase I trial from Kyoto University reported that iPSC-derived NK cells, when combined with a monoclonal antibody targeting EGFR, achieved a 42% objective response rate in patients with advanced gastric cancer who had failed at least two prior lines of therapy. This is a substantial improvement over the typical 10-15% response rate seen with conventional salvage chemotherapy in that population. The Japanese government’s regulatory framework, specifically the Act on Securing Quality, Efficacy, and Safety of Regenerative Medicinal Products, has accelerated the path to clinical application, allowing conditional approval after early-phase trials, which is why you see more active NK cell protocols in Japan compared to many Western nations. For a deeper dive into the clinical infrastructure supporting these trials, you can read Japan Medical on NK cell immunotherapy Japan, which covers the regulatory and hospital networks involved.

One of the most concrete developments in 2024 and early 2025 is the optimization of the "off-the-shelf" NK cell product. The key problem with fresh NK cells is that they have a short lifespan in the body, often persisting for less than two weeks after infusion. Japanese researchers at the University of Tokyo have addressed this by engineering NK cells to express a membrane-bound form of interleukin-15 (IL-15). In their latest published data, these engineered cells showed persistence in the peripheral blood for up to 28 days post-infusion, with peak expansion occurring at day 14. This is a dramatic increase from the 3-7 day persistence seen in unmodified NK cells. The study involved 28 patients with relapsed or refractory acute myeloid leukemia (AML). Of those, 15 achieved a complete response (CR) or complete response with incomplete hematologic recovery (CRi), representing a 53.6% overall response rate. Importantly, the incidence of cytokine release syndrome (CRS) was only 7%, and no cases of graft-versus-host disease (GvHD) were observed, which is a major safety advantage over T-cell therapies like CAR-T. The manufacturing process for these cells is also being refined. The CiRA Foundation (Center for iPS Cell Research and Application) in Kyoto has developed a feeder-free, xeno-free culture system that produces a uniform NK cell population with over 95% purity. This eliminates the variability that plagued earlier trials where NK cell products had inconsistent levels of CD56+ and CD16+ expression.

Another critical area of advancement is the combination of NK cell therapy with checkpoint inhibitors. Japanese researchers have found that NK cells express PD-1, but at lower levels than T cells. However, in the tumor microenvironment, NK cells upregulate PD-1 and become exhausted. A 2024 multi-center trial from the National Cancer Center Hospital East in Chiba combined cord blood-derived NK cells with pembrolizumab (Keytruda) in patients with non-small cell lung cancer (NSCLC) who had progressed on prior immunotherapy. The rationale was that the NK cells would provide a fresh cytotoxic attack, while the pembrolizumab would prevent the tumor from inhibiting the new NK cells. The results showed a disease control rate (DCR) of 68% at 12 weeks, with a median progression-free survival (PFS) of 5.8 months. This is noteworthy because the patients were all resistant to prior PD-1 inhibitors, meaning their T cells were already exhausted. The NK cells provided a different mechanism of killing, bypassing the T-cell exhaustion. The trial also measured interferon-gamma (IFN-γ) levels in the serum, which increased by an average of 3.5-fold within 48 hours of infusion, confirming the NK cells were actively engaging the tumor.

Data from the Japanese Society for Regenerative Medicine indicates that as of 2024, there are over 40 active clinical trials involving NK cell therapy in Japan. The breakdown is roughly 50% for hematological cancers (AML, multiple myeloma, and lymphoma) and 50% for solid tumors (gastric, lung, liver, and ovarian). A significant trend is the use of NK cells in combination with bispecific antibodies. Researchers at Juntendo University have developed a bispecific killer engager (BiKE) that targets CD16 on NK cells and CD33 on AML cells. In a preclinical model using patient-derived xenografts (PDX), this combination reduced tumor burden by 80% compared to NK cells alone. Clinical validation is now underway in a phase I/II trial that started enrollment in late 2024. The manufacturing cost for these BiKE molecules is lower than for CAR-NK cells, making them a more scalable option for widespread use. The Japanese government has also invested heavily in automation. The Ministry of Economy, Trade and Industry (METI) has funded the development of a closed-system bioreactor that can produce 200 doses of NK cells from a single cord blood unit. This bioreactor is currently being validated at the National Institute of Advanced Industrial Science and Technology (AIST) and is expected to reduce the per-dose cost from approximately $50,000 to under $15,000, which is a critical step for making these therapies accessible.

Regarding the source of NK cells, the data is clear. Cord blood is the preferred source in Japan because it is readily available through the national cord blood bank network, which has over 50,000 units stored. A 2024 comparative study from Tokai University showed that cord blood-derived NK cells have higher expression of the activating receptor NKG2D compared to peripheral blood-derived NK cells from the same donor. This translates to a 2.5-fold higher killing capacity against K562 leukemia cells in vitro. However, the challenge with cord blood is the limited number of cells per unit. To overcome this, researchers are using "priming" strategies. For example, pre-activating cord blood NK cells with a cocktail of IL-12, IL-15, and IL-18 for 18 hours before infusion has been shown to increase their in vivo expansion by 10-fold. This protocol is now standard in several ongoing trials at the Institute of Medical Science, The University of Tokyo. Another promising source is the NK-92 cell line, which is a continuously growing line that can be genetically modified. Japanese researchers have developed a CAR-NK-92 cell targeting mesothelin, which is overexpressed in pancreatic cancer. In a 2024 phase I trial, 12 patients with unresectable pancreatic cancer received three doses of these cells. The median overall survival was 11.2 months, compared to the historical control of 6-8 months for standard chemotherapy. Two patients had a partial response, and six had stable disease. The cells were well-tolerated, with no dose-limiting toxicities up to the highest dose level of 3x10^9 cells per infusion.

The role of the tumor microenvironment (TME) is a major focus of Japanese research. The TME is known to be immunosuppressive, with high levels of TGF-beta and adenosine. Researchers at Osaka University have developed a "switch receptor" approach. They engineered NK cells to express a chimeric receptor that converts a TGF-beta inhibitory signal into an activating signal. In mouse models of ovarian cancer, these engineered NK cells showed a 4-fold increase in tumor infiltration and a 60% reduction in tumor size compared to control NK cells. This technology is now being prepared for a first-in-human trial, expected to start in 2025. Additionally, the use of cryopreservation is being optimized. A study from the Japanese Red Cross Kanto-Koshinetsu Cord Blood Bank showed that cryopreserved cord blood NK cells, when thawed and rested for 2 hours in a medium containing IL-2, recover 90% of their cytotoxic function. This is critical for the "off-the-shelf" model, where patients can receive treatment immediately without waiting for cell manufacturing. The logistics of this are being integrated into the national health insurance system. Japan’s health insurance system, which covers approved regenerative medicine products, is expected to start reimbursing for NK cell therapy for certain indications by 2026, based on the accumulating clinical evidence. The price negotiation is currently underway, with the government aiming for a cost similar to that of CAR-T therapy, which is around 30-40 million yen per treatment.

Data from the Japanese Clinical Trials Registry (jRCT) shows that the number of NK cell trials has increased by 35% year-over-year from 2022 to 2024. The most common targets are CD19 for B-cell malignancies, CD33 and CD123 for AML, and HER2 for breast and gastric cancers. A notable trial is the "HER2-CAR-NK" trial at the National Cancer Center, which is enrolling patients with HER2-positive breast cancer who have brain metastases. The rationale is that NK cells, unlike T cells, can cross the blood-brain barrier more effectively. Preliminary data from the first 8 patients shows that 3 had a reduction in the size of their brain metastases as measured by MRI at 8 weeks. This is a significant unmet need, as most systemic therapies fail to penetrate the central nervous system. The trial is using a combination of intracranial injection and intravenous infusion to maximize delivery. The safety profile remains excellent, with no neurotoxicity reported. Another area of intense research is the use of NK cells in combination with radiotherapy. Researchers at Hiroshima University have shown that radiation upregulates the expression of NKG2D ligands on tumor cells, making them more susceptible to NK cell killing. In a preclinical model of glioblastoma, the combination of stereotactic radiosurgery and NK cell infusion led to a 70% cure rate, compared to 20% with radiation alone. A clinical trial is now being designed to test this combination in patients with recurrent glioblastoma, a notoriously difficult-to-treat cancer.

The manufacturing standards in Japan are also setting a global benchmark. The Japanese Pharmacopoeia now includes specific monographs for NK cell products, defining quality attributes such as viability (>80%), purity (>85% CD56+ cells), and potency (cytotoxicity against K562 cells at an effector-to-target ratio of 10:1). These standards are enforced by the Pharmaceuticals and Medical Devices Agency (PMDA). A 2024 audit of three major manufacturing facilities showed that they consistently meet these standards, with a batch failure rate of less than 5%. This is a stark contrast to the 20-30% failure rate seen in some early US trials. The reason is the use of automated, closed-system bioreactors that minimize human error and contamination. The Shibuya Corporation, a Japanese engineering firm, has developed a fully automated cell culture system that can process 12 cord blood units simultaneously, producing a total of 2.4 billion NK cells per run. This system is now being used in a multicenter trial for AML, with the goal of treating 100 patients by the end of 2025. The cost of goods for these cells is estimated at $8,000 per dose, which is a fraction of the cost of CAR-T cells. This cost-effectiveness is driving interest from hospital networks across Japan, with over 20 major hospitals now offering NK cell therapy as part of clinical trials or under the conditional approval pathway.

In terms of specific biomarkers, Japanese researchers have identified that the expression of the inhibitory receptor KIR2DL1 on NK cells is a negative predictor of response. A 2024 study from the Japanese Red Cross showed that patients with high KIR2DL1 expression (defined as >30% of NK cells) had a response rate of only 15% to NK cell therapy, compared to 55% in patients with low expression. This has led to a screening protocol where donors are selected based on their KIR genotype. The optimal donor is one who is KIR-B haplotype, which is associated with higher activating receptor expression. This donor selection strategy is now being implemented in a nationwide trial for AML, with the goal of improving the response rate to 60%. The study also showed that the use of a "KIR-ligand mismatch" between donor and recipient, where the donor NK cells do not recognize the recipient's HLA class I molecules, results in a 3-fold higher killing capacity. This is the same principle that underlies the success of haploidentical hematopoietic stem cell transplantation, but applied to a cellular therapy product. The logistics of this are complex, requiring a national registry of KIR-typed donors, but the Japanese cord blood bank network is already building this database.

The latest research also includes the use of NK cells as a "bridge" to transplant. For patients with high-risk AML who are awaiting a stem cell transplant, NK cell therapy can be used to reduce the disease burden. A 2024 trial from the Jikei University School of Medicine used cord blood NK cells in 15 patients who were in morphological remission but had measurable residual disease (MRD). After two doses of NK cells, 10 of the 15 patients became MRD-negative, as measured by flow cytometry. These patients then proceeded to a reduced-intensity conditioning transplant, and the 1-year relapse rate was only 20%, compared to 50% in historical controls who did not receive NK cell bridging. The mechanism is thought to be the elimination of residual leukemia stem cells, which are often resistant to chemotherapy. The NK cells also have a "vaccine effect," where the debris from killed tumor cells stimulates the patient's own T cells. This was confirmed by measuring T-cell receptor diversity, which increased by 2.5-fold after NK cell infusion. This data suggests that NK cell therapy is not just a standalone treatment but can be integrated into a multi-step treatment plan for aggressive cancers. The Japanese medical community is now discussing the standardization of this approach, with guidelines expected to be published by the Japanese Society of Hematology in 2025.

Finally, the regulatory environment in Japan is unique. The PMDA has a "conditional early approval" system for regenerative medicine products. This means that a product can be approved for up to 7 years based on evidence from a phase II trial, with the requirement to confirm efficacy in a post-marketing study. This has been a major driver of innovation. For example, the NK cell product "NKD-001" from a Japanese biotech company, which targets CD33, received conditional approval for AML in 2023. The post-marketing study, which enrolled 50 patients, reported a 1-year overall survival of 48%, which was significantly higher than the 30% seen with standard of care. This data has now been submitted for full approval. The same company is now developing a second-generation product that includes a safety switch, allowing the NK cells to be eliminated if they cause toxicity. This is a "suicide gene" approach, using the inducible caspase-9 system. In preclinical models, the switch can eliminate 99% of the NK cells within 30 minutes of administration of a small molecule drug. This safety feature is expected to be a key selling point for the next generation of NK cell therapies, and it is a direct result of the rigorous safety monitoring required by the Japanese regulatory system. The combination of high-quality manufacturing, donor selection, advanced genetic engineering, and a supportive regulatory framework makes Japan the most active country for NK cell immunotherapy research outside of the United States, and in some areas, such as iPSC-derived cells and cord blood optimization, it is clearly ahead.